I am writing to confirm that I have now completed my search for the information which you requested on 3 December 2025.
Request
You asked us:
‘As per UIN - 22558 asked by MP Sir Christopher Chope (Tabled on 08-01-2025), which was answered on 14-01-2025 by MP Andrew Gwynne; there were a total of 183 claims of TTS and 224 claims of GBS related to Covid-19 vaccinations, respectively. Out of which 82 claims of VITT/TTS and 63 claims of GBS were successful, respectively. Can you give me the latest or updated figure related to VITT/TTS and GBS at present? Also if you can give me the vaccine type associated with these claims then it will be helpful.’
The NHS Business Services Authority (NHSBSA) received your request on 3 December 2025.
We have handled your request under the Freedom of Information Act 2000 (FOIA).
Our response
I can confirm that the NHSBSA holds the information you have requested. This data is as of 30 November 2025 and relates to COVID-19 vaccine claims received by the Vaccine Damage Payment Scheme.
Fewer than five
Please be aware that I have decided not to release the exact number of awards, where the number is fewer than five. This is because the claimants could be identified when combined with other information that may be in the public domain or reasonably available. Online communities exist for those adversely affected by vaccines they have received. This further increases the likelihood that those may be identified by disclosure of this information.
This information falls under the exemption in section 40 subsections 2 and 3A (a) of the Freedom of Information Act.
This is because it would breach the first data protection principle as:
a) It is not fair to disclose claimant personal details to the world and is likely to cause damage or distress.
b) These details are not of sufficient interest to the public to warrant an intrusion into the privacy of the claimant.
Please click the web link below to see the exemption in full: https://www.legislation.gov.uk/ukpga/2000/36/section/40
Breach of Patient Confidentiality
Please note that the identification of claimants is also a breach of the common law duty of confidence. A claimant who has been identified could make a claim against the NHSBSA for the disclosure of the confidential information.
The information requested is therefore being withheld as it falls under the exemption in section 41(1) ‘Information provided in confidence’ of the Freedom of Information Act.
Please click the below web link to see the exemption in full: https://www.legislation.gov.uk/ukpga/2000/36/section/41
Question:
‘As per UIN - 22558 asked by MP Sir Christopher Chope (Tabled on 08-01-2025), which was answered on 14-01-2025 by MP Andrew Gwynne; there were a total of 183 claims of TTS and 224 claims of GBS related to Covid-19 vaccinations, respectively. Out of which 82 claims of VITT/TTS and 63 claims of GBS were successful, respectively.
Can you give me the latest or updated figure related to VITT/TTS and GBS at present?
Also if you can give me the vaccine type associated with these claims then it will be helpful.’
Total Claims:
The claimant can tell us what happened after vaccination on the claim form. At the medical assessment stage, the medical assessor provides a description of the assessed conditions that they have been able to identify from the claimant's medical records. This can sometimes be a combination of conditions. The condition recorded against each claim may therefore be different to the condition initially stated by the claimant on their original claim form.
The list shows the vaccine identified in the medical records for those where following a medical assessment the named conditions appear as a search term. Claims could be in relation to a combination of both the listed conditions and other conditions.
242 medical assessment reports contain one or more of the following search terms:
vaccine-induced immune thrombotic thrombocytopenia (VITT)
thrombosis with thrombocytopenia syndrome (TTS)
Of these:
217 relate to AstraZeneca
16 relate to Pfizer
6 relate to Moderna
The remainder cannot be categorised because they relate to more than one COVID-19 vaccine. For example, where a claim relates to an initial vaccine from one manufacturer and a booster from another.
There have been 355 claims in relation to Guillain-Barre syndrome (GBS). Of those:
223 relate to AstraZeneca
81 relate to Pfizer
18 relate to Moderna
The remainder cannot be categorised because they relate to more than one COVID-19 vaccine. For example, where a claim relates to an initial vaccine from one manufacturer and a booster from another.
Awarded claims only:
The following information shows specific conditions that have been identified in medical records for those awarded a payment. Claims could be in relation to a mixture of the listed conditions and other conditions.
Submitting a claim in relation to one of the awarded conditions does not mean it will meet the criteria for a Vaccine Damage Payment. This is because each claim is considered on its own merits and in accordance with the criteria of the scheme. VDPS assessments are complex. Each claim is assessed on a case-by-case basis, based upon the individual's medical records, scientific evidence, clinical research and epidemiological evidence.
Under the Vaccine Damage Payments Act 1979 to qualify for a Vaccine Damage Payment, it must be proved that an eligible vaccine was received and:
on the balance of probabilities, the vaccine caused the disability
the resulting disablement is severe
Severely disabled means at least 60% as defined by the principles for assessing the extent of disablement. These are set out in section 103 of the Social Security Contributions and Benefits Act 1992 and the Social Security (General Benefit) Regulations 1982:
https://www.legislation.gov.uk/ukpga/1992/4/contents
https://www.legislation.gov.uk/uksi/1982/1408/schedule/2
112 medical assessment reports contain “VITT” or “TTS” as a search term.
Of those:
112 relate to AstraZeneca
73 medical assessment reports contain “Guillain-Barré syndrome” or “GBS” as a search term. Of those:
73 relate to AstraZeneca
![[Open Data]](/base/images/od_80x15_blue.png)